Immuron Ltd ADR (IMRN)

$0.98 -0.01 (-1.30%)
Market Cap 8.04M
Revenue (ttm) 4.72M
Net Income (ttm) -3.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -71.61%
Debt to Equity Ratio 0.00
Volume 16,300
Avg Vol 560,002
Day's Range N/A - N/A
Shares Out 8.17M
Stochastic %K 37%
Beta 0.79
Analysts Strong Buy
Price Target $5.00

Company Profile

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune su...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9824 5254
Fax: 61 3 9822 7735
Address:
62 Lygon Street, Level 3 Carlton South, Carlton, Australia
Emerging_Growth_Research
Emerging_Growth_Research Jan. 23 at 5:54 PM
$IMRN Emerging Growth Research releases a flash report on $IMRN with a $3.50 price target. The report can be viewed here: https://emerginggrowth.com/wp-content/uploads/2026/01/Immuron-Flash-Report-2026-01-22.pdf
0 · Reply
AlertsAndNews
AlertsAndNews Jan. 19 at 8:33 PM
$IMRN Immuron Reports Continued Sales Growth Global H1 sales reached AUD$4.2M, up 5% YoY, while Q2 sales rose 11% QoQ to AUD$2.2M. Australia delivered the strongest performance, with H1 sales up 13% YoY and Q2 up 11% QoQ, supported by the local launch of ProIBS®. U.S. sales increased 17% YoY in H1 and 8% QoQ in Q2, while Canada saw a sharp sequential rebound despite weaker year-over-year results.
0 · Reply
Rasto2020
Rasto2020 Jan. 13 at 4:57 PM
$IMRN did you guys take it ? 17% gain so far
2 · Reply
DarknessAWAITz
DarknessAWAITz Jan. 13 at 4:33 PM
$IMRN amazing DD behind this ticker. Just do a few mins of research and you will see the potential,
1 · Reply
StockfatherOG
StockfatherOG Jan. 13 at 3:35 PM
$IMRN news any day. Good start to the week.
0 · Reply
Rasto2020
Rasto2020 Jan. 13 at 2:16 PM
$IMRN I like it
0 · Reply
GMExAPE
GMExAPE Jan. 13 at 3:41 AM
$IMRN Immuron Limited does have U.S. Department of Defense–funded research agreements, specifically with the Naval Medical Research Command (NMRC) and the Walter Reed Army Institute of Research (WRAIR). These are real, confirmed, and ongoing programs.. They just were awarded another DoD award last month. Millions secured in non dilutive funding by them last year..should be a $20-$50M MC considering they already have commercialization.
0 · Reply
DarknessAWAITz
DarknessAWAITz Jan. 13 at 3:28 AM
$IMRN
0 · Reply
StockfatherOG
StockfatherOG Jan. 13 at 12:56 AM
$IMRN $400M revenue potential they say…just for one of their treatments. This my good friends..is an absolute gold mine.
0 · Reply
newyork1979
newyork1979 Jan. 12 at 9:10 PM
$IMRN Soon the flock will be chasing this at highs. Better to load here at the dead bottom. NFA!
0 · Reply
Latest News on IMRN
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target

Jan 22, 2026, 6:00 AM EST - 3 days ago

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target

Immuron Reports Continued Sales Growth

Jan 19, 2026, 6:00 AM EST - 6 days ago

Immuron Reports Continued Sales Growth

Immuron IMM-529 IND approved by FDA

Nov 5, 2025, 6:00 AM EST - 2 months ago

Immuron IMM-529 IND approved by FDA

Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target

Oct 17, 2025, 11:07 AM EDT - 3 months ago

Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target

Immuron Q1 FY26 YoY growth

Oct 13, 2025, 6:00 AM EDT - 3 months ago

Immuron Q1 FY26 YoY growth

Immuron Submits IMM-529 IND to FDA

Oct 8, 2025, 6:00 AM EDT - 3 months ago

Immuron Submits IMM-529 IND to FDA

Immuron Letter to Shareholders – Projects Update

Oct 2, 2025, 6:00 AM EDT - 4 months ago

Immuron Letter to Shareholders – Projects Update

Immuron partners with InvestorHub

Aug 26, 2025, 10:29 PM EDT - 5 months ago

Immuron partners with InvestorHub

Immuron - FY25 global sales exceed projection, up 49% on prior year

Jul 17, 2025, 6:00 AM EDT - 6 months ago

Immuron - FY25 global sales exceed projection, up 49% on prior year

Immuron Letter to Shareholders: Projects Update

May 30, 2025, 6:00 AM EDT - 8 months ago

Immuron Letter to Shareholders: Projects Update

Immuron Travelan® highest sales in history

Apr 10, 2025, 6:00 PM EDT - 10 months ago

Immuron Travelan® highest sales in history

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

Mar 5, 2025, 6:00 AM EST - 11 months ago

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

Immuron Travelan® continued strong sales growth

Jan 17, 2025, 6:00 AM EST - 1 year ago

Immuron Travelan® continued strong sales growth

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

Jan 15, 2025, 6:00 AM EST - 1 year ago

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

Immuron Announces Travelan® Clinical Trial Update

Jan 14, 2025, 6:00 AM EST - 1 year ago

Immuron Announces Travelan® Clinical Trial Update

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Dec 2, 2024, 6:00 AM EST - 1 year ago

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Nov 21, 2024, 6:33 PM EST - 1 year ago

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Nov 18, 2024, 8:30 AM EST - 1 year ago

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

Oct 16, 2024, 6:00 AM EDT - 1 year ago

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Oct 4, 2024, 6:30 AM EDT - 1 year ago

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Sep 19, 2024, 9:42 AM EDT - 1 year ago

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Sep 5, 2024, 11:54 AM EDT - 1 year ago

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOSS GOVX

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Aug 16, 2024, 6:00 AM EDT - 1 year ago

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Aug 15, 2024, 6:14 PM EDT - 1 year ago

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Aug 7, 2024, 6:00 AM EDT - 1 year ago

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Immuron requests pre-IND meeting for IMM-529 with FDA filing

Jul 2, 2024, 6:00 AM EDT - 1 year ago

Immuron requests pre-IND meeting for IMM-529 with FDA filing

Immuron Board Changes

May 31, 2024, 6:00 AM EDT - 1 year ago

Immuron Board Changes

Immuron CEO Steven Lydeamore to present at Peak Sky High

May 31, 2024, 6:00 AM EDT - 1 year ago

Immuron CEO Steven Lydeamore to present at Peak Sky High

Immuron Limited to Present at the Emerging Growth Conference

May 7, 2024, 6:00 AM EDT - 1 year ago

Immuron Limited to Present at the Emerging Growth Conference

Immuron Director Resignation

May 3, 2024, 6:00 AM EDT - 1 year ago

Immuron Director Resignation

Immuron to host Live Virtual Event

Apr 15, 2024, 6:00 AM EDT - 1 year ago

Immuron to host Live Virtual Event

Immuron Travelan® sales continued strong growth

Apr 10, 2024, 6:00 AM EDT - 1 year ago

Immuron Travelan® sales continued strong growth

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Mar 7, 2024, 6:00 AM EST - 2 years ago

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Immuron Presentation Australian Biologics Festival 2024

Feb 21, 2024, 6:00 AM EST - 2 years ago

Immuron Presentation Australian Biologics Festival 2024

Immuron achieves record Travelan® sales

Feb 13, 2024, 6:00 AM EST - 2 years ago

Immuron achieves record Travelan® sales

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Feb 8, 2024, 6:00 AM EST - 2 years ago

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Immuron achieves record half yearly Travelan® sales

Jan 16, 2024, 6:00 AM EST - 2 years ago

Immuron achieves record half yearly Travelan® sales

Immuron Clinical Trials Update

Dec 22, 2023, 6:00 AM EST - 2 years ago

Immuron Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Dec 4, 2023, 6:00 AM EST - 2 years ago

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron CEO Steven Lydeamore Investor Webinar Presentation

Nov 13, 2023, 6:00 PM EST - 2 years ago

Immuron CEO Steven Lydeamore Investor Webinar Presentation

Immuron CEO Steven Lydeamore presented at AusBioInvest

Oct 30, 2023, 7:21 AM EDT - 2 years ago

Immuron CEO Steven Lydeamore presented at AusBioInvest

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Oct 18, 2023, 6:00 AM EDT - 2 years ago

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Immuron achieves record quarterly Travelan® sales

Oct 11, 2023, 6:00 AM EDT - 2 years ago

Immuron achieves record quarterly Travelan® sales

Immuron Limited Announces Participation in the LD Micro Main Event XVI

Sep 18, 2023, 7:30 AM EDT - 2 years ago

Immuron Limited Announces Participation in the LD Micro Main Event XVI

Immuron achieves record monthly Travelan® sales

Sep 13, 2023, 6:00 AM EDT - 2 years ago

Immuron achieves record monthly Travelan® sales

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

Immuron to present at the Military Health System Research Symposium

Aug 14, 2023, 6:00 AM EDT - 2 years ago

Immuron to present at the Military Health System Research Symposium

Immuron Announces First Patients Enrolled in Travelan® Clinical Study

Jul 25, 2023, 6:00 AM EDT - 2 years ago

Immuron Announces First Patients Enrolled in Travelan® Clinical Study

Immuron CEO, Steven Lydeamore to present at Bioshares

Jul 24, 2023, 6:00 AM EDT - 2 years ago

Immuron CEO, Steven Lydeamore to present at Bioshares

Emerging_Growth_Research
Emerging_Growth_Research Jan. 23 at 5:54 PM
$IMRN Emerging Growth Research releases a flash report on $IMRN with a $3.50 price target. The report can be viewed here: https://emerginggrowth.com/wp-content/uploads/2026/01/Immuron-Flash-Report-2026-01-22.pdf
0 · Reply
AlertsAndNews
AlertsAndNews Jan. 19 at 8:33 PM
$IMRN Immuron Reports Continued Sales Growth Global H1 sales reached AUD$4.2M, up 5% YoY, while Q2 sales rose 11% QoQ to AUD$2.2M. Australia delivered the strongest performance, with H1 sales up 13% YoY and Q2 up 11% QoQ, supported by the local launch of ProIBS®. U.S. sales increased 17% YoY in H1 and 8% QoQ in Q2, while Canada saw a sharp sequential rebound despite weaker year-over-year results.
0 · Reply
Rasto2020
Rasto2020 Jan. 13 at 4:57 PM
$IMRN did you guys take it ? 17% gain so far
2 · Reply
DarknessAWAITz
DarknessAWAITz Jan. 13 at 4:33 PM
$IMRN amazing DD behind this ticker. Just do a few mins of research and you will see the potential,
1 · Reply
StockfatherOG
StockfatherOG Jan. 13 at 3:35 PM
$IMRN news any day. Good start to the week.
0 · Reply
Rasto2020
Rasto2020 Jan. 13 at 2:16 PM
$IMRN I like it
0 · Reply
GMExAPE
GMExAPE Jan. 13 at 3:41 AM
$IMRN Immuron Limited does have U.S. Department of Defense–funded research agreements, specifically with the Naval Medical Research Command (NMRC) and the Walter Reed Army Institute of Research (WRAIR). These are real, confirmed, and ongoing programs.. They just were awarded another DoD award last month. Millions secured in non dilutive funding by them last year..should be a $20-$50M MC considering they already have commercialization.
0 · Reply
DarknessAWAITz
DarknessAWAITz Jan. 13 at 3:28 AM
$IMRN
0 · Reply
StockfatherOG
StockfatherOG Jan. 13 at 12:56 AM
$IMRN $400M revenue potential they say…just for one of their treatments. This my good friends..is an absolute gold mine.
0 · Reply
newyork1979
newyork1979 Jan. 12 at 9:10 PM
$IMRN Soon the flock will be chasing this at highs. Better to load here at the dead bottom. NFA!
0 · Reply
GMExAPE
GMExAPE Jan. 12 at 8:48 PM
$IMRN already has real revenue coming in with massive non dilutive funding available. Buying all dips.
0 · Reply
HustlerTV
HustlerTV Jan. 12 at 7:22 PM
$IMRN clean as it gets for a bio play
0 · Reply
TheLocoPro
TheLocoPro Jan. 12 at 6:32 PM
$IMRN $2 coming soon. Loading the boat 🚤
0 · Reply
StockfatherOG
StockfatherOG Jan. 12 at 6:26 PM
$IMRN FDA approval already granted and DoD backing. This is going to fly.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 9 at 5:30 PM
$IMRN
0 · Reply
JuggernautRaider
JuggernautRaider Jan. 8 at 12:13 AM
$RVMD congratulations on the likely acquisition by $ABBV 🫡 $IMRN is likely next 🤫
2 · Reply
Baseball89
Baseball89 Jan. 5 at 4:32 AM
$SNSE There was so many ch hype on this. $IMRN ---waking up. Solid and profitable. Cheap too imo
0 · Reply
Baseball89
Baseball89 Jan. 2 at 7:27 PM
$SNSE I knew this was a lot of hype. Waiting till next week. $IMRN Looks solid and cheap too.
0 · Reply
Baseball89
Baseball89 Jan. 2 at 2:36 PM
$SNSE $IMRN waking up soon.
0 · Reply
Baseball89
Baseball89 Jan. 2 at 1:55 PM
$SNSE $IMRN -- going to wake up soon. PT $11-$17. Imo
0 · Reply
Baseball89
Baseball89 Jan. 2 at 1:36 PM
$SNSE $IMRN ---Lets get this one moving. Low float
1 · Reply
Baseball89
Baseball89 Jan. 2 at 11:56 AM
$SNSE $IMRN watching. This one is solid,low float and profitable yr after yr . Let's get the volume on this one.
0 · Reply